CN115427444A - 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法 - Google Patents

用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法 Download PDF

Info

Publication number
CN115427444A
CN115427444A CN202180028613.4A CN202180028613A CN115427444A CN 115427444 A CN115427444 A CN 115427444A CN 202180028613 A CN202180028613 A CN 202180028613A CN 115427444 A CN115427444 A CN 115427444A
Authority
CN
China
Prior art keywords
subjects
ustekinumab
week
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028613.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·约翰斯
K·李
C·马拉诺
R·施特劳斯
H·张
C·奥布莱恩
O·阿德多坤
K·希尔兹-塔特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN115427444A publication Critical patent/CN115427444A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180028613.4A 2020-02-14 2021-02-12 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法 Pending CN115427444A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976582P 2020-02-14 2020-02-14
US62/976582 2020-02-14
PCT/IB2021/051215 WO2021161270A2 (en) 2020-02-14 2021-02-12 Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody

Publications (1)

Publication Number Publication Date
CN115427444A true CN115427444A (zh) 2022-12-02

Family

ID=77271772

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028613.4A Pending CN115427444A (zh) 2020-02-14 2021-02-12 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法

Country Status (11)

Country Link
US (2) US20210253690A1 (https=)
EP (1) EP4103606A4 (https=)
JP (1) JP2023514567A (https=)
KR (1) KR20220141847A (https=)
CN (1) CN115427444A (https=)
AU (1) AU2021218265A1 (https=)
BR (1) BR112022015996A2 (https=)
CA (1) CA3170677A1 (https=)
IL (1) IL295545A (https=)
MX (1) MX2022009987A (https=)
WO (1) WO2021161270A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459191A (zh) * 2014-06-12 2017-02-22 豪夫迈·罗氏有限公司 选择具有修饰的FcRn相互作用的抗体的方法
US20190092853A1 (en) * 2017-09-25 2019-03-28 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
CN108290058B (zh) * 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
TWI744617B (zh) * 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459191A (zh) * 2014-06-12 2017-02-22 豪夫迈·罗氏有限公司 选择具有修饰的FcRn相互作用的抗体的方法
US20190092853A1 (en) * 2017-09-25 2019-03-28 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B.E. SANDS ET AL: "Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis", 《THE NEW ENGLAND JOURNAL OF MEDICINE》, vol. 381, no. 13, 25 September 2019 (2019-09-25), pages 2 *
W. J. SANDBORN ET AL: "Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy", 《ALIMENTARY PHARMACOLOGY &THERAPEUTICS》, vol. 48, no. 1, 24 May 2018 (2018-05-24), pages 3 *

Also Published As

Publication number Publication date
KR20220141847A (ko) 2022-10-20
WO2021161270A9 (en) 2022-03-24
US20210253690A1 (en) 2021-08-19
EP4103606A4 (en) 2024-04-10
US20240002494A1 (en) 2024-01-04
CA3170677A1 (en) 2021-08-19
MX2022009987A (es) 2022-11-10
BR112022015996A2 (pt) 2022-10-11
IL295545A (en) 2022-10-01
WO2021161270A2 (en) 2021-08-19
WO2021161270A3 (en) 2021-09-16
AU2021218265A1 (en) 2022-10-06
EP4103606A2 (en) 2022-12-21
JP2023514567A (ja) 2023-04-06

Similar Documents

Publication Publication Date Title
JP7481423B2 (ja) 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
JP2022500474A5 (https=)
US20240002494A1 (en) Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
US20220112282A1 (en) Method for Treating Crohn's Disease with Anti-IL12/IL23 Antibody
CN118475608A (zh) 用抗il23特异性抗体治疗克罗恩病的方法
US20240294625A1 (en) Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
CN113853385A (zh) 用抗il12/il23抗体治疗儿科受试者的银屑病的方法
EA051461B1 (ru) Безопасный и эффективный способ лечения язвенного колита с помощью антител к il-12/il-23

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination